Navigation Links
Hormone-replacement therapy could hurt heart

Hormone-replacement therapy could increase the risks of coronary heart disease in healthy women, and it has no effect on patients suffering from atherosclerosis, according to two studies released yesterday.
The studies, published in the Aug. 7 issue of the New England Journal of Medicine, expand on the discouraging results of previous studies on the use of estrogen-and-progestin-based hormone replacement therapy //to help combat heart disease.

This study and others like it "clearly tell us that estrogen and progestin should not be used to treat atherosclerosis in women who already have cardiovascular disease," noted Dr. Howard Hodis, who led the study. Hormone therapy in healthy women is most often used to ease the uncomfortable side effects of menopause, such as hot flashes.

The results of the other study released yesterday offered equally little encouragement for healthy women. The study of 16,000 women, expected to take eight years, was called to a halt after five years because the risks were found to outweigh the benefits, according to officials at Harvard Medical School.

The researchers found there was an increased risk of heart disease after the first year of estrogen and progestin therapy in otherwise healthy postmenopausal women. "This treatment should not be prescribed for the prevention of cardiovascular disease," the authors concluded.
'"/>




Page: 1

Related medicine news :

1. Acupuncture May Help Chemotherapy Side Effects
2. Antioxidants protect health tissue in people undergoing radiation therapy.
3. Distraction therapy found very effective in postoperative patients
4. Acupuncture superseeds massage therapy for short term relief of pain
5. Ovarian cancer in relationship with Hormone therapy
6. New therapy better at increasing bone density
7. Gene therapy - Aim to improve blood flow
8. Gene therapy restores sight
9. Heat therapy relieves back pain
10. Radiotherapy helps in colon cancer
11. New therapy for pimples
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... ... 2017 , ... The Boulevard is honored to host Shriners and Masons Children’s ... located in the Main West Entrance of The Boulevard (in front of JCPenney). ... necessary and each child with a parent or guardian will be photographed for free ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... News Advisory/Interview ... Choice has helped score a major victory in Europe for public health and the ... , Based on rigorous scientific research and the overwhelming support of European citizens, ...
(Date:3/23/2017)... ... March 23, 2017 , ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: ... A Legacy” is the creation of published author, Desiree M Webb, a registered nurse, ... She has been happily married to her husband, Paul, for over twenty-nine years. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden ... innovative patient - centric payment system, to expand its focus on patient care ... patient financial experience. , “At Ogden Clinic, we are working to become ...
(Date:3/23/2017)... ... ... Trainer”: an electrifying and suspenseful gunslinger novel with a twist. “The Trainer” is ... an enthusiasm for action and adventure stories. , Published by Christian Faith ... at the thirty-three notches that lined the edges of the wooden grip plates of ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 ... Enterprises Limited, anuncia el nombramiento de Stuart ... una plataforma de servicios integrados completa para su ... un cargo clave en el crecimiento y ejecución ... será responsable de impulsar todas las actividades de ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
(Date:3/23/2017)... March 23, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" ... specialty pharmaceutical company, is pleased to announce that ... approval from the U.S. Food and Drug Administration ... ("ANDA") for tetrabenazine tablets in the 12.5 mg ... is a generic equivalent of the branded product ...
Breaking Medicine Technology: